metrics. Patients who agreed to participate filled out written informed consent and filled out paper questionnaires in clinic or at home. All results have been entered into a database. Patients with five forms of arthritis, fibromyalgia and osteoporosis were questioned. In order to validate the accuracy of self-reporting, patients self-reported diagnoses and medications were compared to those recorded in their medical record by members of the rheumatology team. In this audit, we present the results of the accuracy of self-reported diagnoses for the first 274 patients. Results: 274 participant questionnaires were reviewed. Diagnostic agreement was generally good: 2/3 or higher except for the lowest ankylosing spondylitis at 24% and gout at 44%. The highest recorded was the fibromyalgia cohort at 88%. Conclusion: The accuracy of patients' self-reported diagnoses attending a rheumatology outpatient clinic was generally good with the exception of gout and ankylosing spondylitis. These data should help projections for self-reported diagnoses at a national level. Disclosures: The authors have declared no conflicts of interest. Background: Inflammatory arthritides are chronic conditions which require a multi-disciplinary team approach to management. Rheumatoid arthritis is characterised by flares of joint pain, stiffness and fatigue and can progress to joint deformity and disability. This can affect an individual's ability both to perform everyday dental hygiene tasks and their ability to access dental services. Previous studies have found an association between gum disease and inflammatory arthritis, specifically rheumatoid arthritis. It is therefore important that patients with inflammatory arthritis have easy access to dental care and information on good dental hygiene. This audit aimed to assess the need and use of dental services in patients with inflammatory arthritis in an inner city tertiary hospital outpatient clinic setting. Methods: Patients with inflammatory arthritis who presented to general rheumatology outpatients over a period of 3 months, were asked to complete a questionnaire. Data was then analysed using excel.
Background: There is currently much interest in changing the way musculoskeletal (MSK) elective services are run both nationally (NHS England), regionally (sustainable transformation partnerships), and locally (GP commissioning). Through triage, standardised referrals and ideally a single point of access, the drive is to have people see the right person, in the right place, at the right time. Although rheumatology is traditionally part of MSK elective care, there is a significant autoimmune systemic disease component that lies outside the combined scope of other specialties involved in MSK (orthopaedics, physiotherapy, primary care). This study looks at what a real-world rheumatology service encompasses so that future MSK pathways triage patients correctly and do not delay patients who would benefit from early diagnosis and treatment (e.g. early inflammatory arthritis, lupus, vasculitis). This ensures better patient experience, quality of care, and clinical outcomes. Here we look at referrals to a busy district general hospital (DGH) rheumatology department to ascertain the scope of work of a rheumatology service in an urban area. Methods: All patients who were referred to the Croydon University Hospital Rheumatology department for their first appointment were collected within a three-month period. 406 referrals were made from 1 April to 30 June 2017. Data was collected from both electronic and paper patient records. 103 patients were excluded in total. This was due to incomplete notes (n ¼ 20), non-attendance (n ¼ 8), cancellation (n ¼ 27), or if the appointment had not yet taken place at the time of data collection in September 2017 (n ¼ 48). Results: 303 new attendees were included in our analysis. 76% were female. The mean age was 52 (17-96). The commonest ethnicity was White British (40%). 24% were referred through the early inflammatory arthritis route, 16% through consultant-to-consultant referral, 11% through choose and book, 8% through the osteoporosis route, 4% through the musculoskeletal clinical assessment and triage service (MCATS), 37% were miscellaneous referrals. The most common diagnoses at first appointment were inflammatory arthritis (42%), osteoarthritis (15%), and osteoporosis (15%). 13% had a non-inflammatory soft tissue diagnosis. 3% did not have a rheumatology diagnosis. 72% had at least one comorbidity. 47% had two or more comorbidities. The commonest comorbidity was a further rheumatological disease (26%). 12% were discharged from their first appointment. 94% of investigations were completed within 6 weeks. Blood tests (97%), X-ray (94%), MRI (94%), USS (78%), other (80%). Of osteoporosis patients, 50% were prescribed parenteral drug therapy, and 10% went onto oral. 7% had supplementations. 67% had no treatment prescribed. Conclusion: A small percentage of referrals to this DGH rheumatology service had no rheumatological problem. 12% were discharged from their first appointment. This snapshot of a rheumatological service can inform future patient pathways to get it right first time. Metrology indices such as Bath Ankylosing Spondylitis Metrology Index (BASMI) are pivotal for the initial assessment and evaluation of clinical outcomes. In Sheffield Teaching Hospitals, patients with AS are followed up in either the dedicated AS clinic or general rheumatology clinic. In the dedicated clinic, they are reviewed by a physiotherapist on the day of their appointment. Self-help advice is given and BASMI measurements recorded. Further follow up is arranged if indicated. The general clinic does not have immediate access to physiotherapy and referrals have to be made by a clinician. This audit aimed to assess the rate of physiotherapy referral for patients in the general clinic and compare the rate of BASMI measurements with those in the dedicated clinic. (Using recommendations that BASMI should be measured at least annually). Methods: In February 2017, a total of 365 patients with AS attended the general clinic and 115 patients attended the dedicated AS clinic. Systematic sampling was used to choose 50 patients from the general clinic and 25 patients from the dedicated clinic. Physiotherapy notes were used to confirm physiotherapy input and BASMI measurements. To account for possible confounders such as current use of biologics; this information was obtained using the biologics database. Results: Only nine out of 50 (18%) patients in the general clinic were seen by physiotherapy and had BASMI measurements recorded within one year. This increased slightly to 14 patients within two years. In the dedicated clinic, a far greater proportion: 18 out of 25 (72%) Here we show the impact of a collaborative pathway between neurology, acute medicine, vascular surgery and rheumatology to assess and treat patients suspected of having GCA. The management and the service was benchmarked against the British Society of Rheumatology guidelines. Aim of this audit is to assess the impact of a new GCA pathway at Croydon University Hospital on the diagnosis and management of patients referred for suspected GCA. Methods: A retrospective review of electronic patient records was carried out for patients who presented to the hospital with clinically suspected GCA in a three month period (1/11/15-31/1/16) before implementation of the new pathway (cycle 1) and in a three month period (1/1/17-31/3/2017) after pathway implementation (cycle 2). Data was collected on admission and discharge dates, demographics, inflammatory markers, symptoms and the final diagnosis. In addition, data was collected on neurology and ophthalmology involvement, medications including steroid dose, availability and quality of the biopsy and histopathology report. Patients who were previously diagnosed with GCA were excluded from this study. Results: There were 12 patients in cycle 1 and six in cycle 2. For cycle 1 and 2, the results respectively were: mean age 61 and 67; a female predominance of 83.3% and 66.7%; final diagnosis of GCA in 16.7% and 50%; average time taken for biopsy since initiation of steroids decreased from 6.4 to 4.5 days; percentage of biopsies carried out within a week of initiation of steroids improved from 66.6% to 100%; time taken for biopsy from referral to surgeon improved from 6.4 to 3 days; average length of the biopsy improved from 9 mm to 14 mm; percentage of biopsies greater than 10 mm in length improved from 11.1% to 100% of biopsies. No patients were discussed with neurology in cycle 1 versus 50% in cycle 2. Conclusion: As a rare disease, this audit has a small sample size. Yet we feel that this novel collaborative pathway has demonstrated a positive impact on the service provided to patients who present with suspected GCA. This new pathway has reduced the number of patients being put on high dose steroids unnecessarily for presumed GCA, increased the yield of true GCA from those referred and increased the local awareness of this rare but significant disease. The pathway has also highlighted how multi-disciplinary involvement (including neurology) is key in ensuring that the GCA mimics (half of the patients who had a biopsy) are adequately diagnosed and managed. Background: Cyclophosphamide is a chemotherapy agent which has immunosuppressant properties and is used to treat a number of auto inflammatory diseases including interstitial lung disease, vasculitis and systemic lupus erythematosus (SLE). Pulsed intravenous cyclophosphamide infusions are generally delivered in a day case setting. There are a number of common mild, and less frequent severe, side effects which patients should be made aware of prior to treatment to allow appropriate counselling and avoid unnecessary risks. In our specialist unit, patients receive counselling by a consultant and are given a patient information leaflet prior to commencing cyclophosphamide treatment. Further counselling is given on the day of the first pulse by a specialist nurse and a formal consent form is signed. Little is known about the effectiveness of the current counselling schedule and the subsequent retention of the information provided. We sought to assess the knowledge of patients receiving cyclophosphamide. Methods: Over a three week period, 34 patients at a range of different stages of treatment, filled in a questionnaire assessing their knowledge of the treatment, the risk of infection and other potential side effects. The questionnaire was based on the written information sheet. Results: All patients recalled being counselled prior to their treatment (100%) and 91% knew who to contact if they had problems with their treatment. However, knowledge of the infection risk was below our standard with only 71% aware they should avoid people with chicken pox and only 50% aware that they would not receive their cyclophosphamide while on antibiotics. 65% knew to seek medical attention if they became pyrexial. Only 21% new they needed their bloods taken up to 5 days before the cyclophosphamide. Conclusion: There are concerning gaps in knowledge of patients interviewed, particularly relating to infection risk of cyclophosphamide and generally the retention of information was poor, best viewed as 50-30% unsure of core safety knowledge. This could result in the potential for adverse outcomes, for example, patients with active infection delaying seeking medical attention or inappropriately attending the DCU for further immunosuppressive treatment. We are trailing new methods of reinforcing the information giving e.g. credit cards with information summarised on it, reinforcement at each treatment visit from medical and nursing staff. We will re-audit the effectiveness of these interventions in the future. Disclosures: The authors have declared no conflicts of interest. Background: TICORA was the first study to demonstrate tight control in rheumatoid arthritis led to better clinical and radiographic outcomes compared to routine care. The first evaluation of tight control concepts in PSA was with the TICOPA study in 2015. Treatment naive early disease patients were randomised to receive either tight control management or standard care. The tight control group were reviewed four-weekly and had their treatment escalated if the MDA criteria was not met as per their protocol. The standard care group were seen for a 12 weekly review and treatment modified by consultant preference. At 48 weeks the study showed that patients in the tight control arm were more likely to achieve ACR20, 50 and 70 with no difference in adverse events. After the TICOPA paper patients were referred for tight control of their PSA within the Belfast Trust. The aim was to commence patients on DMARDs with a new diagnosis of PSA with review every 4 weeks with both the nurse specialist and medical team. Nurse specialist performed baseline joint and skin scores and treatment is escalated as per the TICOPA paper. Methods: We reviewed the notes of the patients referred to the tight control strategy since 2014 within the Belfast Trust. We wanted those who had been enrolled for at least 48 weeks to compare outcomes with the TICOPA paper. Results: 20 patients who had 48 weeks of data available. There was 12 males and eight females who were all diagnosed with PSA by a consultant rheumatologist. All patients were DMARD naïve. All patients in first 3 months were seen every four weeks and then all patients at six months were seen at least every six weeks for review. In 5/20 cases sulfasalazine was used as first line DMARD therapy and no patients got to MDA whilst on sulfasalazine monotherapy. Of those on methotrexate, MDA was achieved in 7/15 cases at three months. Three patients were escalated to biologics at six months. Overall at 48 weeks ten patients were escalated to biologic therapy. At 48 weeks ACR 20 was seen 70% (14/20), ACR 50 in 55% (11/20) and ACR 70 in 15% (3/20) of patients with similar outcomes to the TICOPA paper. Conclusion: Tight control in clinical practice will yield results but is time consuming. Benefits include regular review to get on top of
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